Phenotypical alterations induced by glucocorticoids resistance in RPMI 8226 human myeloma cells

Resistance to glucocorticoids (GCs) frequently appears during treatment of hematological malignancies. This study investigates the phenotypical alterations observed in human myeloma cell sublines resistant to glucocorticoids. Using the RPMI8226 cell line, the cytotoxic efficiencies of four glucocort...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2004-03, Vol.28 (3), p.307-313
Main Authors: Genty, Vincent, Dine, Gérard, Dufer, Jean
Format: Article
Language:English
Subjects:
Antigens, CD - analysis
Cell Line, Tumor - drug effects
Cell Line, Tumor - pathology
Dexamethasone - pharmacology
Drug Resistance, Neoplasm - drug effects
Gene Expression Regulation, Neoplastic - drug effects
Glucocorticoids
Glucocorticoids - pharmacology
Humans
Methylprednisolone - pharmacology
Multiple Myeloma - pathology
Myeloma cell line
Phenotype
Prednisolone - pharmacology
Prednisone - pharmacology
Resistance
RPMI 8226 cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Resistance to glucocorticoids (GCs) frequently appears during treatment of hematological malignancies. This study investigates the phenotypical alterations observed in human myeloma cell sublines resistant to glucocorticoids. Using the RPMI8226 cell line, the cytotoxic efficiencies of four glucocorticoids, and the phenotypes of isolated resistant sublines were analyzed. Methyl-prednisolone and dexamethasone exhibited the higher toxic effects on RPMI8226 cells. All corticoids were able to induce drug-resistance. Resistant sublines showed an increased expression of the α-isoform of the glucocorticoid receptors (GRs), and specific modulations in CD23, CD38, CD44 and CD58 expressions. Thus, glucocorticoid resistance in RPMI8226 cells is accompanied by significant phenotypical alterations that could be implicated in survival enhancement to therapy and/or tumor spreading.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2003.08.009